Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (17)

2023

  1. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

2022

  1. Author Correction: EMPReSS: standardized phenotype screens for functional annotation of the mouse genome (Nature Genetics, (2005), 37, 11, (1155), 10.1038/ng1105-1155)

    Nature Genetics

  2. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

2021

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

    European Journal of Immunology, Vol. 51, Núm. 12, pp. 2708-3145

2019

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

2018

  1. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598

2015

  1. Identification of six new susceptibility loci for invasive epithelial ovarian cancer

    Nature Genetics, Vol. 47, Núm. 2, pp. 164-171

2014

  1. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

    PLoS Genetics, Vol. 10, Núm. 4

2007

  1. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones

    Drug Metabolism and Disposition, Vol. 35, Núm. 10, pp. 1873-1879

  2. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk

    Molecular and Cellular Biology, Vol. 27, Núm. 4, pp. 1247-1253

2006

  1. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion

    Drug Metabolism and Disposition, Vol. 34, Núm. 4, pp. 690-695

  2. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk

    Carcinogenesis, Vol. 27, Núm. 1, pp. 123-130

2005

  1. Human cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine

    Journal of Pharmacology and Experimental Therapeutics, Vol. 312, Núm. 1, pp. 144-152

  2. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver

    Molecular Pharmacology, Vol. 67, Núm. 5, pp. 1765-1771

  3. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin

    Molecular Pharmacology, Vol. 67, Núm. 5, pp. 1758-1764

  4. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk

    Nature Medicine, Vol. 11, Núm. 2, pp. 127-129

  5. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2)

    Drug Metabolism and Disposition, Vol. 33, Núm. 5, pp. 614-618